Talking About Feeling: Axogen Raises Awareness for Mastectomy Side Effect
In the wake of Breast Cancer Awareness Month, UF startup and UF Innovate | Accelerate at Sid Martin Biotech graduate Axogen has expanded the scope of a campaign to raise awareness about a side effect of mastectomies.
New Outcomes Data Demonstrating Prolonged Survival for Inoperable Pancreatic Cancer Patients
UF startup ViewRay, Inc., a leading medical technology company that provides groundbreaking MRI-guided radiation therapy, announced that the results of a multi-center study of 148 inoperable pancreatic cancer patients treated with MRIdian SMART (MR-guided stereotactic adaptive radiation therapy) were presented as part of the Annual Meeting of the American Society for Radiation Oncology (ASTRO), the world's largest radiation oncology society.
University of Florida Innovators Honored at 4th Annual Standing InnOvation Event
On a sunny and fresh fall afternoon, UF Innovate | Tech Licensing hosted its annual event to recognize top innovations stemming out of the University of Florida. More than 150 innovators and entrepreneurs attended the in-person event, and around 40 joined the livestream to celebrate their achievements in fiscal year 2021.
Resilience Turns to Harvard for Biologics Manufacturing Tech, Inks 5-Year R&D Pact
Resilience, a company developing technologies that overcome the challenges of manufacturing complex biological medicines, is turning to Harvard University to find some of those new solutions.
Cannabix Achieves New Benchmark for FAIMS Marijuana Breathalyzer Technology
UF startup Cannabix Technologies Inc., developer of marijuana breathalyzer devices for law enforcement and the workplace, reports that engineers have made major advancements on its high-field asymmetric waveform ion mobility spectrometry (FAIMS) breathalyzer for analyze sensitivity and portability.
Atsena Therapeutics Unveils XLRS Gene Therapy Program Leveraging Novel Spreading Capsids
UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, unveiled its preclinical gene therapy program for X-linked retinoschisis (XLRS), a monogenic disease caused by mutations in the RS1 gene.
Rain Neuromorphics Tapes Out Demo Chip for Analog AI
UF startup and UF Innovate | Accelerate graduate Rain Neuromorphics, which incubated at The Hub, has taped out a demonstration chip for its brain-inspired analog architecture that employs a 3D array of randomly-connected memristors to compute neural network training and inference at extremely low power.
AavantiBio Furthers Strategic Partnership With University of Florida To Research and Develop Next Generation Gene Therapy Capsids
UF startup and UF Innovate | The Hub resident AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, announced it is partnering with the University of Florida to research and develop next generation gene therapy capsids with the goal of creating safer, more effective, and tissue specific gene therapies.
ViewRay Announces 510(k) Pending Status of the Newest Generation of MRIdian Innovations
UF startup ViewRay, Inc., a leading medical technology company that provides groundbreaking MRI-guided radiation therapy, announced that the company has received acceptance from the FDA on their recent submission for new MRIdian features focused on enhancing on-table adaptive workflow efficiency and expanding clinical utility.
Dialectic Therapeutics Announces First-in-Human Dose in Phase 1 Clinical Trial Evaluating DT2216, Its First Generation Antiapoptotic Protein Targeted Degradation (APTaD™) Compound, in Patients With Relapsed or Refractory Malignancies
UF startup Dialectic Therapeutics, Inc., a Texas-based clinical-stage biotechnology company focused on creating innovative new technologies to treat cancer, announced the dosing of the first patient in a first-in-human, dose-escalation Phase 1 trial evaluating DT2216, the first generation compound built using its proprietary and novel Antiapoptotic Protein Targeted Degradation (APTaD™) technology, in patients with relapsed or refractory solid tumor and hematologic malignancies.
